Correction to: Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center

Yosuke Kano¹ · Manabu Ohashi¹ · Naoki Hiki¹ · Daisuke Takahari² · Keisho Chin² · Kensei Yamaguchi² · Yasuo Tsuda¹ · Yoshiaki Shoji¹ · Itaru Yasufuku¹ · Kojiro Eto¹ · Satoshi Ida¹ · Koshi Kumagai¹ · Souya Nunobe¹ · Takeshi Sano¹

Published online: 13 June 2018

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Correction to: Gastric Cancer

<https://doi.org/10.1007/s10120-018-0827-9>

In the original publication of this article, the 5-year OS rates of the S-1 group in the ACTS-GC according to TNM-6 were described incorrectly in Table 4. The revised Table 4 is given in this correction.

Table 4 Comparison of 5-year overall survival and recurrence-free survival in this study and the ACTS-GC according to the JC-13 and TNM-6

	RFS				OS			
	JC-13		TNM-6		JC-13		TNM-6	
	This study (%)	ACTS-GC S-1 group (%)	This study (%)	ACTS-GC S-1 group (%)	This study (%)	ACTS-GC S-1 group (%)	This study (%)	ACTS-GC S-1 group (%)
II	83.2	79.2	83.4	77.9	86.6	84.2	87.6	83.4
IIIA	67.4	61.4	73.9	64.3	73.6	67.1	79.1	68.9
IIIB	49.5	37.6	44.4	35.9	57.0	50.2	50.0	43.7
IV	60.0		39.0	26.8	60.0		47.1	45.1

JC-13 Japanese Classifications 13th edition, ACTS-GC Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer, TNM-6 the Union for International Cancer Control 6th edition and American Joint Committee on Cancer 6th edition, RFS recurrence-free survival, OS overall survival

The original article can be found online at <https://doi.org/10.1007/s10120-018-0827-9>.

✉ Manabu Ohashi
manabu.ohashi@jfc.or.jp

¹ Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan

² Department of Gastroenterological Medicine, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan